SCHEMBL10134833

SCHEMBL10134833

COC(=O)c1ccc2c(c1)nc(Nc1ccc(F)cc1)c1cscc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 7/20 0.56
PDE5A O76074 2/20 0.48
ABCG2 Q9UNQ0 2/20 0.48
ABCC1 P33527 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TNF P01375 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
NR2F2 P24468 1/20 0.46
MCL1 Q07820 1/20 0.46
KLF5 Q13887 1/20 0.46
NOD1 Q9Y239 1/20 0.46
TP53 P04637 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134828 0.91 CSNK2A1 (0.53) CSNK2A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL10134817 0.87 CSNK2A1 (0.68) CSNK2A1
SCHEMBL10134830 0.82 CSNK2A1 (0.58) CSNK2A1PDE5AABCG2LMNATP53
SCHEMBL13688023 0.78 CSNK2A1 (0.44) CSNK2A1ABCG2MEN1KMT2AMAPT
SCHEMBL10134805 0.78 CSNK2A1 (0.68) CSNK2A1
SCHEMBL10134745 0.77 CSNK2A1 (0.59) CSNK2A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL10134753 0.74 ABCG2 (0.43) CSNK2A1ABCG2MEN1KMT2AMAPT
SCHEMBL4974839 0.72 CSNK2A1 (1.00) CSNK2A1
SCHEMBL10132495 0.72 CSNK2A1 (0.79) CSNK2A1
SCHEMBL8885713 0.72 CSNK2A1 (0.81) CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885PDE5A 1334/4885ABCG2 2980/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885PDE5A 1334/4885ABCG2 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.